(SeaPRwire) – Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024
Halle (Saale) / Munich, Germany, May 15, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its first quarter financial results for the period ended March 31, 2024 and provide a corporate update on Thursday, May 23, 2024. The Company will host a conference call and webcast open to the public.
Conference call details
Date: May 23, 2024
Time: 3:00 pm CEST / 9:00 am EDT
The conference call will be available via phone and webcast.
The live audio webcast of the call will be available on Vivoryon ́s website at:
To join the conference call via phone, participants may pre-register and will receive dedicated dial-in details to easily and quickly access the call via the following website:
It is suggested participants dial into the conference call 15 minutes prior to the scheduled start time to avoid any delays in attendance.
###
About Vivoryon Therapeutics N.V.
Vivoryon adalah syarikat bioteknologi klinikal yang memberi tumpuan kepada pembangunan perubatan molekul kecil inovatif. Didorong oleh semangat ilmu dan inovasi yang hebat, Syarikat berusaha untuk mengubah kehidupan pesakit yang memerlukan yang menghidapi penyakit serius. Syarikat memanfaatkan kepakaran mendalamnya dalam memahami pengubahsuaian selepas penyahpembentukan untuk membangunkan ubatan yang mengubah suai aktiviti dan kestabilan protein yang diubah suai dalam keadaan penyakit. Syarikat telah menubuhkan saluran ubatan kecil molekul oral yang boleh didapati untuk pelbagai indikasi termasuk penyakit Alzheimer, gangguan radang dan fibrotic, termasuk kepada buah pinggang, dan kanser.
Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.
For more information, please contact:
Investor Contact
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Tel: +49 (0)345 555 99 30
Email:
Media Contact
Trophic Communications
Valeria Fisher
Tel: +49 175 8041816
Email:
Artikel ini disediakan oleh pembekal kandungan pihak ketiga. SeaPRwire (https://www.seaprwire.com/) tidak memberi sebarang waranti atau perwakilan berkaitan dengannya.
Sektor: Top Story, Berita Harian
SeaPRwire menyampaikan edaran siaran akhbar secara masa nyata untuk syarikat dan institusi, mencapai lebih daripada 6,500 kedai media, 86,000 penyunting dan wartawan, dan 3.5 juta desktop profesional di seluruh 90 negara. SeaPRwire menyokong pengedaran siaran akhbar dalam bahasa Inggeris, Korea, Jepun, Arab, Cina Ringkas, Cina Tradisional, Vietnam, Thai, Indonesia, Melayu, Jerman, Rusia, Perancis, Sepanyol, Portugis dan bahasa-bahasa lain.